Detalhe da pesquisa
1.
Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.
Cancer Rep (Hoboken)
; 7(3): e1954, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38441358
2.
Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel.
Biomark Res
; 11(1): 73, 2023 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37491309
3.
Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer.
Med
; 2(6): 736-754, 2021 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34223403
4.
Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer.
JCO Precis Oncol
; 3: 1-26, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35100698
5.
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.
Cancer Res
; 78(18): 5243-5258, 2018 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30012670
6.
Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.
Cancer Med
; 4(8): 1289-93, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25871911